ImmunityBio has established a dedicated European sales infrastructure to support the commercialization of Anktiva, its bladder cancer treatment, across 30 countries. The company has assembled an 85-person sales force in partnership with Accord Healthcare, which will serve as the distribution partner for the pharmaceutical asset in the region. To facilitate these operations, ImmunityBio created an Irish subsidiary that will anchor the company's European distribution strategy.
The sales expansion represents a significant step in ImmunityBio's international growth strategy, allowing the company to directly engage healthcare providers and build market presence for Anktiva beyond its domestic market. The structured approach, combining a dedicated sales team with an established distribution partner, aims to optimize market penetration across diverse healthcare systems in Europe.
Market reaction to the announcement remained muted, with IBRX shares declining 2.75% in premarket trading. The modest pullback reflected broader market conditions rather than concerns about the commercial initiative itself.